Differential effectiveness of tyrosine kinase inhibitors in 2D/3D culture according to cell differentiation, p53 status and mitochondrial respiration in liver cancer cells

Sorafenib and Regorafenib are the recommended first- and second-line therapies in patients with advanced hepatocellular carcinoma (HCC). Lenvatinib and Cabozantinib have shown non-inferior antitumoral activities compared with the corresponding recommended therapies. The clinical trials have establis...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodríguez-Hernández, María A., Chapresto-Garzón, Raquel, Cadenas, Miryam, Navarro-Villarán, Elena, Negrete, María, Gómez-Bravo, Miguel A., Victor, Victor M., Padillo, Francisco J., Muntané, Jordi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7206079/
https://www.ncbi.nlm.nih.gov/pubmed/32382022
http://dx.doi.org/10.1038/s41419-020-2558-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7206079/
https://www.ncbi.nlm.nih.gov/pubmed/32382022
http://dx.doi.org/10.1038/s41419-020-2558-1

Ejemplares similares